Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI · NASDAQ Global Select
-$0.15 today
Vol 2.73M · Avg 2.42M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:MRVI · Revenue to Net Income
Key Ratios
Analysis
$204.7M of revenue converted into -$104.6M of net income for the selected period. Gross margin is 26.4% and net margin is -55.5%, showing how much revenue survives after costs and taxes. EPS is $-0.73, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $185.7M -28.3% | $259.2M -10.3% | $288.9M -67.3% | $883.0M +10.5% | $799.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $152.4M +1.0% | $150.9M +1.4% | $148.7M -12.0% | $169.0M +20.2% | $140.6M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $33.4M -69.2% | $108.3M -22.7% | $140.2M -80.4% | $714.0M +8.4% | $658.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 18.0% -23.8pp | 41.8% -6.7pp | 48.5% -32.3pp | 80.9% -1.5pp | 82.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $23.3M +21.4% | $19.2M +11.2% | $17.3M -5.9% | $18.4M +20.7% | $15.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $171.5M +6.0% | $161.8M +6.9% | $151.4M +17.1% | $129.3M +29.2% | $100.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $40.1M -88.3% | $343.9M +100.1% | $171.8M +22.9% | $139.8M +34.4% | $104.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $60.9M +7.0% | $56.9M +16.6% | $48.8M +28.0% | $38.1M +53.9% | $24.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$147.1M +6.2% | -$156.9M -122.0% | $712.4M +16.8% | $610.0M +4.1% | $585.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -79.2% -18.7pp | -60.5% -307.1pp | 246.6% +177.5pp | 69.1% -4.2pp | 73.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$6.7M +97.1% | -$235.6M -644.5% | -$31.6M -105.5% | $574.2M +3.5% | $554.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -3.6% +87.3pp | -90.9% -80.0pp | -11.0% -76.0pp | 65.0% -4.4pp | 69.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $23.9M -12.6% | $27.4M -1.2% | $27.7M +1085.9% | $2.3M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $27.0M -43.4% | $47.7M +3.9% | $45.9M +124.8% | $20.4M -32.5% | $30.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$228.2M -782.4% | -$25.9M -104.0% | $649.4M +2955.2% | -$22.7M +4.8% | -$23.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$235.0M +10.1% | -$261.5M -142.3% | $617.7M +12.0% | $551.5M +3.9% | $530.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -126.5% -25.6pp | -100.9% -314.7pp | 213.8% +151.3pp | 62.5% -4.0pp | 66.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$4.2M -126.5% | -$1.9M -100.2% | $756.1M +1143.4% | $60.8M -1.1% | $61.5M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$130.8M +9.7% | -$144.8M -21.7% | -$119.0M -154.1% | $220.2M +21.0% | $182.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -70.4% -14.5pp | -55.9% -14.7pp | -41.2% -66.1pp | 24.9% +2.2pp | 22.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +13.3% | -$1 -16.7% | -$1 -153.9% | $2 +5.0% | $2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +13.3% | -$1 -16.7% | -$1 -153.9% | $2 +7.1% | $2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $145.1M +5.2% | $137.9M +4.5% | $131.9M +0.3% | $131.5M +14.6% | $114.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $145.1M +5.2% | $137.9M +4.5% | $131.9M +0.2% | $131.7M +8.0% | $122.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.67B
Septerna, Inc.
NASDAQ:SEPN
$1.57B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.52B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.39B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.25B
Kura Oncology, Inc.
NASDAQ:KURA
$853.25M
Replimune Group, Inc.
NASDAQ:REPL
$835.63M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$581.39M
Prime Medicine, Inc.
NASDAQ:PRME
$562.62M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$189.18M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MRVI generate?
Maravai LifeSciences Holdings, Inc. (MRVI) reported $185.74M of revenue in fiscal 2025.
Is MRVI profitable?
Maravai LifeSciences Holdings, Inc. (MRVI) reported -$130,773,000.00 of net income, with a net margin of -70.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.